Prelude Therapeutics Inc (PRLD)
4.77
+0.16
(+3.47%)
USD |
NASDAQ |
Mar 27, 16:00
4.76
-0.01
(-0.21%)
After-Hours: 20:00
Prelude Therapeutics Total Liabilities (Quarterly): 40.58M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 40.58M |
September 30, 2023 | 20.25M |
June 30, 2023 | 18.55M |
March 31, 2023 | 23.02M |
December 31, 2022 | 25.06M |
September 30, 2022 | 24.92M |
June 30, 2022 | 18.21M |
March 31, 2022 | 18.86M |
Date | Value |
---|---|
December 31, 2021 | 19.20M |
September 30, 2021 | 19.98M |
June 30, 2021 | 15.22M |
March 31, 2021 | 13.26M |
December 31, 2020 | 11.41M |
September 30, 2020 | 11.37M |
June 30, 2020 | 102.06M |
December 31, 2019 | 71.28M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
11.37M
Minimum
Sep 2020
102.06M
Maximum
Jun 2020
28.33M
Average
19.59M
Median
Total Liabilities (Quarterly) Benchmarks
CEL-SCI Corp | 16.06M |
AIM ImmunoTech Inc | 5.259M |
IGC Pharma Inc | 2.206M |
NovaBay Pharmaceuticals Inc | 5.815M |
Protalix BioTherapeutics Inc | 50.86M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 277.66M |
Shareholders Equity (Quarterly) | 237.09M |